Search

Displaying results 9501 - 9510 of 10000 in total
  1. Drug

    Efocipegtrutide

    go.drugbank.com/drugs/DB18194
    Investigational

    Efocipegtrutide is a long-acting, monomeric peptide triple agonist.

  2. Drug

    PT217

    go.drugbank.com/drugs/DB18472
    Investigational

    PT217 is a bispecific Antibody against DLL3 and CD47

  3. Drug

    Chelerythrine

    go.drugbank.com/drugs/DB17024
    Experimental

    A benzophenanthridine alkaloid evaluated as a kinase-inhibitor.[A252982]

  4. Drug

    PD-169316

    go.drugbank.com/drugs/DB17040
    Experimental

    PD-169316 is a p38 MAP kinase inhibitor.[A253062]

  5. Drug

    PD-173952

    go.drugbank.com/drugs/DB17041
    Experimental

    PD-173952 is a potent Myt1 kinase inhibitor.[A253067]

  6. Drug

    MRK-409

    go.drugbank.com/drugs/DB13993
    Experimental

    MRK-409 is a GABA-A receptor agonist [A31972].

  7. Drug

    Veldoreotide

    go.drugbank.com/drugs/DB12777
    Investigational

    Somatoprim is under investigation for the treatment of Acromegaly.

  8. Drug

    Atrazine

    go.drugbank.com/drugs/DB07392
    Experimental

    Atrazine is a selective triazine herbicide. Inhalation hazard is low and there are no apparent skin manifestations or other toxicity in humans.

  9. Drug

    AAV9/MFSD8

    go.drugbank.com/drugs/DB18616
    Experimental

    AAV9/MFSD8 is a gene therapy developed by Neurogene Inc. … It is an adeno-associated virus serotype 9 (AAV9) vector with an engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8

  10. Drug

    MYR-101

    go.drugbank.com/drugs/DB17075
    Investigational

    ASPA is produced in oligodendrocytes, and participates in the metabolism of N-acetylaspartate (NAA). … Canavan disease is a fatal childhood genetic disorder characterized by white matter degeneration in the brain.